By Stephen McConnell (August 7, 2017, 12:27 PM EDT) -- The U.S Food and Drug Administration cannot get out of its own way on the issue of off-label communications. Its power to punish off-label promotion comes from an odd regulatory two-step, whereby off-label promotions are said to prove an indicated use not included in the label and, thus, not accompanied by adequate directions for use — making the product misbranded. The tortured path of this "logic" should, by itself, render this off-label regulatory regime questionable, but the FDA's recent reaffirmance of it amounts to incoherent defiance.
The FDA takes the position that a company's truthful, non-misleading statements about off-label use can...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!